Amplia Adds Ovarian Trial After Pancreatic Success
Amplia Therapeutics (ASX:ATX) has opened a new chapter in its drug story. On 8 May, the small-cap biotech announced a partnership with the Australia New Zealand Gynaecological Oncology Group (ANZGOG) to test its lead drug, narmafotinib, in ovarian cancer. The new study, called PRROSE, will treat patients with high-grade serous ovarian cancer who don’t respond well to standard chemotherapy. For investors, this is more than just another trial. It signals that narmafotinib could work across multiple cancers, not just pancreatic ones. We believe this strengthens the long-term case for ATX as a broader platform play, even though the near-term value still rests with the pancreatic data.
What are the Best ASX Stocks to invest in right now?
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
Why Ovarian Cancer Is the Logical Next Step for Narmafotinib
Narmafotinib targets a protein called FAK (focal adhesion kinase). That may sound technical, but the idea is simple. FAK helps cancer cells build a tough, fibrous shield around tumours that blocks chemotherapy from getting in. Both pancreatic and ovarian tumours over-produce FAK, so the science behind the move is solid.
The PRROSE trial will enrol 15 to 20 patients and combine narmafotinib with two standard chemo drugs, carboplatin and paclitaxel. It will focus on the roughly 20% of ovarian cancer patients who don’t respond to first-line platinum-based chemotherapy before surgery. This is a clear unmet need where treatment options run out fast.
What makes this deal especially attractive is the structure. ANZGOG is an investigator-initiated network of more than 1,650 members across hospitals, universities and research bodies in Australia and New Zealand. That gives Amplia access to top clinical infrastructure without paying the full cost. In our view, this transforms ATX from a single-cancer bet into a broader FAK platform story.
ACCENT Pancreatic Data Remains the Real Value Driver
While ovarian cancer adds optionality, pancreatic data is what underpins ATX today. The mature ACCENT trial data, centrally reviewed in March 2026, delivered an objective response rate of 35.9% (23 of 64 patients), well ahead of the 23% MPACT benchmark. Even more striking, 5 patients achieved a complete response, a 7.8% rate, which Amplia describes as unprecedented in this setting. Median overall survival reached 11.1 months versus 8.5 months for chemotherapy alone. Narmafotinib also holds FDA Fast Track and Orphan Drug designations.
Investors should note one recent setback. In April 2026, Amplia paused recruitment in its AMPLICITY trial after dose-limiting toxicities tied to the FOLFIRINOX chemotherapy, not narmafotinib itself. The company is now exploring alternative combinations. This makes the ovarian move look well-timed.
For FY25 (ended March 2025), Amplia reported revenue of A$3.78m and losses of A$6.57m.
The Investors’ Takeaway for Amplia
At a market cap of around A$67 million and trading near A$0.13, ATX sits firmly in speculative small-cap biotech territory. The stock has been highly volatile. We believe the ANZGOG deal strengthens the long-term case but doesn’t move near-term catalysts. Investors should watch fresh ACCENT updates, new pancreatic combination plans, PRROSE enrolment progress, and the cash burn rate. This stock suits only risk-tolerant investors comfortable with binary clinical outcomes.
